Hudson Bay Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Hudson Bay Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-76,500	Closed	-$1.41M	–	763
2024 Q1	$1.41M	Buy	+76,500	New	+$1.9M	0.01%	505
2021 Q4	–	Sell	-171,000	Closed	-$2.84M	–	1075
2021 Q3	$2.84M	Buy	+171,000	New	+$3.3M	0.04%	549
2020 Q3	–	Sell	-30,000	Closed	-$1.45M	–	536
2020 Q2	$1.45M	Buy	+30,000	New	+$1.44M	0.03%	343
2019 Q4	–	Sell	-70,000	Closed	-$2.52M	–	420
2019 Q3	$2.52M	Buy	+70,000	New	+$2.12M	0.07%	233
2018 Q4	–	Sell	-150,000	Closed	-$3.11M	–	762
2018 Q3	$3.11M	Buy	+150,000	New	+$2.36M	0.04%	388

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Hudson Bay Capital Management's ACAD Position: Q2 2026 in Review

Hudson Bay Capital Management increased its Acadia Pharmaceuticals (ACAD) stake by 4.4% in Q2 2026, buying an estimated $429K and bringing the position to 465,000 shares worth $11.8M. The position accounts for 0.03% of the portfolio, ranked #326.

Hudson Bay Capital Management first reported a position in ACAD in Q1 2017 and has held it in 26 quarters since. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Hudson Bay Capital Management held 465,000 shares of Acadia Pharmaceuticals worth $11.8M as of Q2 2026.
Hudson Bay Capital Management bought 19,494 Acadia Pharmaceuticals shares in Q2 2026, an estimated $429K.
Acadia Pharmaceuticals made up 0.03% of Hudson Bay Capital Management's portfolio in Q2 2026, its #326 holding.
Hudson Bay Capital Management first reported a position in Acadia Pharmaceuticals in Q1 2017 and has held it in 26 quarters since.
353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.